Notably, cladribine showed significant efficacy against MS in a large, randomized study, reinforcing our findings that inhibiting CD99 function could be a key mechanism behind the therapeutic effects of cladribine observed in patients with MS [74]. This evidence concerns the gene CD99 and myeloid sarcoma.